LifeSci Advisors, LLC
LifeSci Advisors Announces 12th Board Appointment Through Its Board Placement Initiative
LifeSci is pleased to share that Dr. Carol L. Brosgart has joined the Board of Directors of ABIVAX, a biotechnology company harnessing the immune system to develop a functional cure for HIV and treatments for inflammatory/autoimmune diseases and cancer. Dr. Brosgart is a Clinical Professor of Medicine, Epidemiology and Biostatistics at the Institute for Global Health, Department of Medicine, University of California in San Francisco, CA.
"I am pleased to join the board of ABIVAX and help this progressive company continue to advance their clinical pipeline forward," said Dr. Brosgart . "I look forward to contributing to the strategic and clinical development oversight of the company, and I am thankful to LifeSci for facilitating this placement."
Dr. Brosgart has served as an independent director on the Boards of both public and privately-held biotechnology companies, as a member of the Federal US CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment, and was the Senior Advisor on Science and Policy to the Division of Viral Hepatitis at the CDC. She has held numerous senior management positions within biotechnology and health care. Dr. Brosgart was the Chief Medical Officer for Alios BioPharma (now Johnson & Johnson), a biotech company developing therapies to treat viral diseases. Dr. Brosgart joined Alios from Children's Hospital & Research Center in Oakland, California, where she served as Senior Vice President and Chief Medical Officer. For eleven years Dr. Brosgart held a number of senior management positions at Gilead Sciences. While Vice President of Clinical Research at Gilead she was responsible for the clinical development and approval by the FDA and by regulatory authorities worldwide of two antiviral therapies - Viread® for the treatment of HIV, and Hepsera® for the treatment of chronic hepatitis B.
Prior to Gilead, Dr. Brosgart worked for more than 20 years in public health, clinical care, research, and teaching. She was among the first physicians in the United States to recognize and treat patients with HIV/AIDS. Dr. Brosgart was the founding Medical Director of the East Bay AIDS Center. She led NIH clinical trials as a member of the Community Programs for Clinical Research on AIDS (CPCRA), chaired the CPCRA Scientific Advisory Committee, and contributed to HIV antiretroviral drug development, and to the development of prophylactic and treatment agents for opportunistic and malignant complications of HIV. Dr. Brosgart received her B.S. in community medicine from the University of California, Berkeley (UCB), her M.D. from the University of California, San Francisco (UCSF), and her residency training in Pediatrics (UCSF) and Public Health and Preventive Medicine (UCB). She has published extensively in the areas of infectious diseases, focusing on antiviral therapy for HIV, HBV, CMV and related public health policy.
"We are confident that Carol's insights and experience will be a huge asset to ABIVAX as they continue to develop their clinical programs," said Michael Rice, President and Co-Founder, LifeSci Advisors . "We're very happy to have made the introduction and look forward to announcing more successful appointments through our Board Placement Initiative in the near future."
"We are thrilled that Carol is bringing her expertise and deep industry knowledge to our board," said Dr. Hartmut J. Ehrlich, Chief Executive Officer, ABIVAX. "Her vast wealth of experience and passion for treating patients with HIV/AIDS will be invaluable to the company's clinical strategy, and we are pleased to have found Dr. Brosgart through LifeSci's Board Placement Initiative."
LifeSci Advisors' Board Placement Initiative (BPI) was launched with the goal of helping companies in the life sciences industry diversify and strengthen their company boards. Introductions between companies and eligible board candidates are made after LifeSci has met with a company's management team or Board regarding the skills and expertise they are seeking in a candidate, and after the LifeSci team has properly vetted the board candidates. BPI now has helped to place 12 women on corporate boards and is looking to continue this success. With a proprietary network comprised of board-ready women, LifeSci Advisors hopes that BPI can become a valuable platform where both female executives and life sciences companies are able to network and to grow.
BPI is accepting resumes from interested candidates and referrals on an on-going basis. To find out how you can use the BPI network for your next board candidate search, visit www.lifesciadvisors.com/board-diversity-initiatives . Inquiries, resume submissions, and open board seat referrals can be sent to firstname.lastname@example.org .
LifeSci Advisors, LLC
) is the largest investor relations consultancy in the life sciences industry, founded to provide companies with a multi-faceted approach to investor communications and outreach. With a global focus and reach, the firm provides the highest quality service for its clients through its deep sector specialization. LifeSci's team of MDs and PhDs enables the firm to better understand clients' R&D, regulatory and commercial strategies, and its team of financial services, investor relations and public relations specialists helps clients effectively communicate to the marketplace. This combination of life sciences, financial services, and investor relations competencies allows LifeSci Advisors to provide an invaluable and unique service offering to clients.
LifeSci Partners (www.lifescipartners.com ) is the leading provider of consulting services in the areas of investor relations, public relations, corporate communications and capital markets advisory. Combining deep domain expertise in the life sciences with decades of experience in capital markets and public relations, LifeSci Partners delivers unparalleled services to life sciences companies globally.
Information om Globenewswire
Følg pressemeddelelser fra Globenewswire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Globenewswire
ThalesNano Inc.17.8.2018 11:01 | pressemeddelelse
ThalesNano Energy Introduces H-Genie™: Revolutionary Compact, High Pressure Hydrogen Gas Generation Platform for Chemists
Bombardier Inc.15.8.2018 22:49 | pressemeddelelse
Bombardier Establishes Automatic Securities Disposition Plan
Cisco15.8.2018 22:06 | pressemeddelelse
Cisco Reports Fourth Quarter and Fiscal Year 2018 Earnings
Open Society Foundations15.8.2018 17:23 | pressemeddelelse
Open Society Names New Head of West Africa Foundation
SharesPost15.8.2018 15:01 | pressemeddelelse
Huobi Joins GLASS Network and Invests in SharesPost
Corel14.8.2018 15:12 | pressemeddelelse
Pinnacle Studio 22 Ultimate Amps Up Video Editing with New Pro-inspired Features
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum